Diaccurate appoints 4 world-class experts to head its scientific board

Diaccurate, a spin-off from the Pasteur Institute, which designs and develops a novel immunotherapy approach against HIV and cancers, announces the composition of its Scientific Advisory Board (SAB). Including 5 world-class experts, the SAB encompasses all aspects of the new approach of the company, called trans CD4 immunotherapy: the physiopathology of CD4 T-cells, that of cell membranes, the development of therapeutic antibodies and the HIV.

As Diaccurate's first drug candidate, the “sole-in-class” antibody anti-PLA2G1B, advances towards the clinic, the SAB will work with the management team and will advise Diaccurate on the scientific and technological aspects of its proprietary platform and on the implementation of its first-in-man in HIV.

Today, the company has entered a new phase in its short history as, after having established the pre-clinical proof-of-concept of its approach in HIV and developed an innovative trans-CD4 immunotherapy platform for infectious diseases and cancers, Diaccurate is preparing the future clinical trial of its first drug candidate in HIV” says Dr. Philippe Pouletty, Co-founder and Chairman of Diaccurate, Co-founder and Life Science General Manager of Truffle Capital. “The complementarity expertise and experience of the members of our Scientific Board will be a major asset to guide us in this key step.”

We are developing a totally novel immunotherapy approach which aims to restore the function of lymphocytes at the heart of all immune responses: CD4 T-cells” says Prof. Jacques Thèze, Co-founder, CEO and CSO of Diaccurate. “Besides its broad potential of applications, this approach could allow us to ultimately reach the goal shared by the global AIDS community: the functional cure of HIV-infected patients. I am extremely proud that our team’s ambition is shared by a panel of such prominent scientists.”

Diaccurate is the result of a major discovery: the mechanism responsible for the anergy of CD4 T-cells in HIV-infected patients. Since then, it has developed an antibody that is able to block this deleterious mechanism and thus restore the function of these lymphocytes” comments Prof. Luc Teyton, Professor in the Department of Immunology and Microbiology of the prestigious Scripps Research Institute and Chairman of the SAB. “Through this approach, Diaccurate opens up a new space in the booming field of immunotherapy, a strategy which could be applied to other diseases as the anergy of CD4 T-cells is common to many infections and cancers. I am very excited to be contributing to this great scientific, medical and entrepreneurial adventure.”